Link to Jan18 ASM Webcast added to website (Events). I don't see anything about CEO Roger Lias' Jan8/Monday presentation at "Biotech Showcase 2018" being webcast.
= = = = = = = = = 1-8-18: Name=>AVID, Tickers=CDMO/CDMOP, History of CDMO Transition “...Effective at market open on Monday, Jan. 8, 2018, trading for Avid Bioservices will begin under the symbol “CDMO”… Preferred stock will begin trading under “CDMOP”… The corp. name change to Avid Bioservices does not affect the rights of the company’s stockholders and no action is required by stockholders… Outstanding stock certificates are not affected by the name change and will not need to be exchanged.” https://tinyurl.com/y8vhjow4 - - - - - - - - Full History of CDMO Transition & Ronin: PR’s, Letters, 13-D’s, Form4’s, and Proxy’s https://tinyurl.com/ycb3fpfm
"An updated corporate website featuring a new logo will be available at http://www.avidbio.com as of market open on Monday, Jan. 8, 2018." This from the end of the "ABOUT AVID" section of today's PR. https://tinyurl.com/y8vhjow4
IHUB premium folks...look at the chart on right. Already CDMO headed. Trouble is that CDMO identifies a different stock and its chart...Cadence OPT August 15(CDMO)...001
This will make many millionaires in due time, patience people! They know what they are doing an what is to come or this would not be real! Enough said, gl all $$$$
1-18-18/2017 ASM: Roger Lias’ Slideshow & Attendee Reports ...Attendee Reports are after the Slides. I will update & re-post as more come in over the next few days.
CEO Roger Lias’ ASM Presentation Slides (1-18-18):
ATTENDEE REPORTS (2017 ASM 1-18-18):
By: Hawkfan1 (Michael) 1-18-18 9:41pmET #322974 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137796412 Here are some of my notes taken at the ASM. They are very brief paraphrases, since I never took shorthand in school. As usual, Brandon Cox was the first to take the microphone with a long list of questions, that at least this shareholder very much appreciated. Q. You are burning $3-4mm/qtr, with no cash and no back log. How do you plan to raise capital? A. Your estimate of our burn rate is in the right ball park. We do have $33mm in backlog, but that is quite conservative. Most companies recognize all of an order when it is placed, but traditionally, PPHM has only recognized backlog as work orders for that order are placed. But clearly, we need more capital. We must eliminate the 'going concern' clause. While it may not be ideal for a small biotech, it is probably something they can live with. But for a manufacturing company, it is a death knell. Customers need to know that you are going to be around for the long term. Q. How dilutive will it be? A. We don't know yet. We don't know how much we will need yet. Q. Is anyone from the old management team working to help sell the R&D technology? A. Yes, Shelly. And others are working as consultants. Q. Most CDMO's are private companies. Are there any plans to take the company private? A. Not currently. (He did mention, kind of jokingly, that it would be nice). Q. Who are the major institutional investors? A. Still Ronan, Tappan, and Eastern Capital. Q. Will they be involved in the capital raise? A. Hopefully. Q. What is the cost of being a public company? A. About $2-3mm/year. Q. As a strictly mfg. company, do we really need 7 board members? A. Right now, the experience that they all bring is extremely helpfull. Down the road, maybe not. Q. How much cash do we currently have? A. $27.7mm. (Not quite sure I got this right, but I think that $10mm was in customer deposits). [NOTE: the $27.7mm is a/o 10-31-17, the last 10-Q (Deposits were $13.1mm): https://tinyurl.com/ybycb2s6 ] Q. Will Avid expand beyond the earthquake prone Tustin area? A. It could be done relatively easily. Down the road, it will be evaluated. Then Brandon relinquished the mike and North40k gave a long and impassioned commentary about various trials and people (such as Dr. Wolchok) that the company should contact about Bavituximab. He mentioned Wolchok's comment that his next trial "depends on the company". Dr. Lias stated that Dr. Wolchok has not contacted the company. He mentioned that an associate of Dr. Wolchok had said that it will be 18 mos. before the next trial proceeds. (This was met with incredulity from several shareholders in attendance). Dr. Lias stated that they have numerous discussions regarding CAR-T, but there was no interest. In some other discussions, they found our technology interesting, but then said "prove it in a trial". N40k then asked if the recent Halozyme trial failure would affect Avid. It will not. Brandon Cox then resumed his questioning. He asked a question regarding the IP patent clock, which I previously reported. For continuity, Dr. Lias's answer was that as patents start to expire, and a BP realizes that it will take about $70mm and 3-4 years to bring a product to market, a 5-year patent life is not that exciting to them. Q. How much Bavi do we have in storage? A. Enough for a couple of small trials, nothing big. Q. Client #1 is Halozyme. We don't know the name of client #2, but are they gone for good? A. No, but I don't expect them to be hugely successful. They will be years down the road. Q. Question regarding the interest in the Exosome test kit. A. Not much commercial interest. Q. Are you trying to sell the IP in bits and pieces or as a package deal? A. While a package deal would be ideal, not gonna happen. Then Greg got up and asked about the process of sell the IP. Dr. Lias commented that there was not much interest. The previous board has talked to everyone - it is not a secret - just not much interest. Then N40k asked the board to contact Precision for Medicine, which concluded the Q&A. Again, this is very roughly paraphrased from my notes. Other members that were in attendance, please correct anything that I may have inadvertently gotten wrong. As I decided to take the tour, I was not able to talk to the board members one on one after the meeting. BY: HAWKFAN1 (MICHAEL) ... 1-18-18 7:54pmET #322954 (INITIAL POST) https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137794640 Dr. Lias comment about the lack of interest in the IP by BP was in response to a question by Brandon Cox about the declining IP clock. His example was that if BP knows that it will take about $70M and 3-4 years of trials to get a drug to market, then a 5-year patent life is just not that exciting to them. This doesn't address the question of getting a patent extension, however. If this is true, then Dr. Lias needs to be made aware of it. FU #323010: Just a few more general impressions from the meeting today. Like the rest of you, I was very disappointed in the approach to marketing the IP. On the one hand, Dr. Lias said that there were on-going discussions that he could not talk about, but he continually down played any expectation that we would receive much value for it. It was almost like they have already given up and have a 'Hey, we tried, but nobody is interested' attitude. They certainly didn't spell out any detailed marketing plan. On the CDMO front, they generally impressed me as qualified, and will probably do a fine job, but I almost choked when Lias said that Tracy Kinjersky "hit the ground running". Hopefully, she will not emulate Mary Boyd. The tour of the Myford facility was as impressive as ever. The 2 new 2000L reactors are installed, tested and ready to go, but have not yet been used in production. Someone asked how many employees we have now and we were told about 200, of which 30 something (I don't remember the exact number) are in production. I asked, if only 30 something are in production, what do the others do? I was told quality control, testing, etc., which I would consider as part of production. This brought the number up to about 75. Unfortunately, we were interrupted, and I wasn't able to pursue this breakdown any further. It seems reasonable to me that we can get to $200mm in sales, but it will be at least 2-3 years down the road. They already have space in the Myford building to build out a duplicate of the existing facility, except that I believe it will use all 2000L reactors. But this space is still raw warehouse space, and will take a minimum of a year to build. And they won't start building it until they have reached significant profits from the exiting facility. So it all hinges on how fast they can attract new clients.
By: Holotawoopas 1/18/18 4:49pmET #322902 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137790910 For those who have pinned their hopes on the value of the IP it is time to mourn your loss and move on as there was nothing concrete about any potential monetizing extrapolated at the ASM. N40 gave a valiant effort to plead the case of value of the IP but IMO it fell on deaf ears! The CEO said no BP interest has been received! FU#322909: The CEO stated that the biggest down fall to monetizing the IP has nothing to do with leverage but has everything to do with patent expiration!!!
By: Eb0783 1/18/18 1:45pmET #322864 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137783413 ASM votes: #1 all re-elected, #2 for 36.4mm, #3 for 15.2 v. against 3.6, #4 1 year FU#322879: Per Lias, there is no formal process, group, or investment bank in place to sell the IP. FU#322934: Lias said he wasn't a patent expert when made those comments about short patent life being an issue. It was obvious he wasn't aware that patents could be extended due to years lost in development. Some of us took that short patent life excuse with a grain of salt.
FULL HISTORY of PPHM-Ronin PR’s, Letters, 13-D’s, Form4’s, Proxy’s, etc: https://tinyurl.com/ycb3fpfm 12-26-17: Roger Lias replaces Steven King as Pres./CEO; in process of changing name to Avid Bio. and new Nasdaq Ticker ("early 2018") https://tinyurl.com/yb34e2t8
12-11-17: Qtly. Conf. Call (Lias/Lytle) Transcript https://tinyurl.com/ybycb2s6 ...Dr. Lias, "the company is undergoing a broad-scale transformation, the goals of which are to shift complete focus to the Avid Bioservices CDMO business and the complete divestiture of all of Peregrine's legacy R&D assets, which include bavituximab."
1-18-18/2017 ASM: Roger Lias’ Slideshow & Attendee Reports ...Attendee Reports are after the Slides. I will update & re-post as more come in over the next few days.
CEO Roger Lias’ ASM Presentation Slides (1-18-18):
ATTENDEE REPORTS (2017 ASM 1-18-18):
By: Hawkfan1 (Michael) 1-18-18 9:41pmET #322974 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137796412 Here are some of my notes taken at the ASM. They are very brief paraphrases, since I never took shorthand in school. As usual, Brandon Cox was the first to take the microphone with a long list of questions, that at least this shareholder very much appreciated. Q. You are burning $3-4mm/qtr, with no cash and no back log. How do you plan to raise capital? A. Your estimate of our burn rate is in the right ball park. We do have $33mm in backlog, but that is quite conservative. Most companies recognize all of an order when it is placed, but traditionally, PPHM has only recognized backlog as work orders for that order are placed. But clearly, we need more capital. We must eliminate the 'going concern' clause. While it may not be ideal for a small biotech, it is probably something they can live with. But for a manufacturing company, it is a death knell. Customers need to know that you are going to be around for the long term. Q. How dilutive will it be? A. We don't know yet. We don't know how much we will need yet. Q. Is anyone from the old management team working to help sell the R&D technology? A. Yes, Shelly. And others are working as consultants. Q. Most CDMO's are private companies. Are there any plans to take the company private? A. Not currently. (He did mention, kind of jokingly, that it would be nice). Q. Who are the major institutional investors? A. Still Ronan, Tappan, and Eastern Capital. Q. Will they be involved in the capital raise? A. Hopefully. Q. What is the cost of being a public company? A. About $2-3mm/year. Q. As a strictly mfg. company, do we really need 7 board members? A. Right now, the experience that they all bring is extremely helpfull. Down the road, maybe not. Q. How much cash do we currently have? A. $27.7mm. (Not quite sure I got this right, but I think that $10mm was in customer deposits). [NOTE: the $27.7mm is a/o 10-31-17, the last 10-Q (Deposits were $13.1mm): https://tinyurl.com/ybycb2s6 ] Q. Will Avid expand beyond the earthquake prone Tustin area? A. It could be done relatively easily. Down the road, it will be evaluated. Then Brandon relinquished the mike and North40k gave a long and impassioned commentary about various trials and people (such as Dr. Wolchok) that the company should contact about Bavituximab. He mentioned Wolchok's comment that his next trial "depends on the company". Dr. Lias stated that Dr. Wolchok has not contacted the company. He mentioned that an associate of Dr. Wolchok had said that it will be 18 mos. before the next trial proceeds. (This was met with incredulity from several shareholders in attendance). Dr. Lias stated that they have numerous discussions regarding CAR-T, but there was no interest. In some other discussions, they found our technology interesting, but then said "prove it in a trial". N40k then asked if the recent Halozyme trial failure would affect Avid. It will not. Brandon Cox then resumed his questioning. He asked a question regarding the IP patent clock, which I previously reported. For continuity, Dr. Lias's answer was that as patents start to expire, and a BP realizes that it will take about $70mm and 3-4 years to bring a product to market, a 5-year patent life is not that exciting to them. Q. How much Bavi do we have in storage? A. Enough for a couple of small trials, nothing big. Q. Client #1 is Halozyme. We don't know the name of client #2, but are they gone for good? A. No, but I don't expect them to be hugely successful. They will be years down the road. Q. Question regarding the interest in the Exosome test kit. A. Not much commercial interest. Q. Are you trying to sell the IP in bits and pieces or as a package deal? A. While a package deal would be ideal, not gonna happen. Then Greg got up and asked about the process of sell the IP. Dr. Lias commented that there was not much interest. The previous board has talked to everyone - it is not a secret - just not much interest. Then N40k asked the board to contact Precision for Medicine, which concluded the Q&A. Again, this is very roughly paraphrased from my notes. Other members that were in attendance, please correct anything that I may have inadvertently gotten wrong. As I decided to take the tour, I was not able to talk to the board members one on one after the meeting. BY: HAWKFAN1 (MICHAEL) ... 1-18-18 7:54pmET #322954 (INITIAL POST) https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137794640 Dr. Lias comment about the lack of interest in the IP by BP was in response to a question by Brandon Cox about the declining IP clock. His example was that if BP knows that it will take about $70M and 3-4 years of trials to get a drug to market, then a 5-year patent life is just not that exciting to them. This doesn't address the question of getting a patent extension, however. If this is true, then Dr. Lias needs to be made aware of it. FU #323010: Just a few more general impressions from the meeting today. Like the rest of you, I was very disappointed in the approach to marketing the IP. On the one hand, Dr. Lias said that there were on-going discussions that he could not talk about, but he continually down played any expectation that we would receive much value for it. It was almost like they have already given up and have a 'Hey, we tried, but nobody is interested' attitude. They certainly didn't spell out any detailed marketing plan. On the CDMO front, they generally impressed me as qualified, and will probably do a fine job, but I almost choked when Lias said that Tracy Kinjersky "hit the ground running". Hopefully, she will not emulate Mary Boyd. The tour of the Myford facility was as impressive as ever. The 2 new 2000L reactors are installed, tested and ready to go, but have not yet been used in production. Someone asked how many employees we have now and we were told about 200, of which 30 something (I don't remember the exact number) are in production. I asked, if only 30 something are in production, what do the others do? I was told quality control, testing, etc., which I would consider as part of production. This brought the number up to about 75. Unfortunately, we were interrupted, and I wasn't able to pursue this breakdown any further. It seems reasonable to me that we can get to $200mm in sales, but it will be at least 2-3 years down the road. They already have space in the Myford building to build out a duplicate of the existing facility, except that I believe it will use all 2000L reactors. But this space is still raw warehouse space, and will take a minimum of a year to build. And they won't start building it until they have reached significant profits from the exiting facility. So it all hinges on how fast they can attract new clients. FU#323064: re: How many in meeting? I didn't actually count, but I was going to guess that there were probably about 20 shareholders, and we were matched, if not outnumbered, by company employees. My impression was that it was a bit smaller attendance by shareholders than in years past.
By: Holotawoopas 1/18/18 4:49pmET #322902 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137790910 For those who have pinned their hopes on the value of the IP it is time to mourn your loss and move on as there was nothing concrete about any potential monetizing extrapolated at the ASM. N40 gave a valiant effort to plead the case of value of the IP but IMO it fell on deaf ears! The CEO said no BP interest has been received! FU#322909: The CEO stated that the biggest down fall to monetizing the IP has nothing to do with leverage but has everything to do with patent expiration!!!
By: Eb0783 1/18/18 1:45pmET #322864 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137783413 ASM votes: #1 all re-elected, #2 for 36.4mm, #3 for 15.2 v. against 3.6, #4 1 year FU#322879: Per Lias, there is no formal process, group, or investment bank in place to sell the IP. FU#322934: Lias said he wasn't a patent expert when made those comments about short patent life being an issue. It was obvious he wasn't aware that patents could be extended due to years lost in development. Some of us took that short patent life excuse with a grain of salt. FU#323063: re: How many in meeting? I counted about 40 at the start of the meeting. I would guess 50%-60% were shareholders. That is about normal from my experience. I remember counting 40 & 50 in previous ASMs. FU#323066: The thing is, if they are really not having a process, group, or IB in place to evaluate/sell our IP, they don't have to spend anything to do it. At the very least, give the task to some IB or 3rd party expert on contingency: you can keep 50% of whatever you can sell it for. (You lawyers often take cases on the same basis and accept 30, 40, 50% quite often). I said that to Lias after the meeting, with Ziebell & Lytle standing there - no comment from them. I find their stance on this incredulous, if true!
By: Djohn 1-19-18 2:18pmET #323067 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137818937 MY THOUGHTS AFTER THE ASM: I missed the fancy danish, the cream cheese and bagels also missed the fancy hotel backdrop making me think we were on the verge of something astronomical. What did not miss was my thoughts of how many shares had to be sold to pay for me to bite on my bagel, sip on my fine coffee while looking at a beautiful swimming pool at a posh hotel. It’s amazing what can be done with a couple of cases of bottled water, one pot of coffee and a room with chairs. That alone convinced me our new leadership is serious about how they spend the shareholders money! For me the ASM went as I expected. It just confirmed to me that we are no longer chasing a dream. We no longer have a questionable cast of characters spending our money diluting our shares. It’s pretty easy, we are a manufacturing company now with basic straight forward business model. We have people in place who are qualified to grow this business and IMO recoup the total amount I invested in PPHM maybe even more. I have given up the dream! I will awake daily and put on a BaviDermCQ patch. I will develop a 12-step program to wean myself from astronomical thoughts. One of those steps will be to not visit this board as often. Another step will be to fully investigate the members of the BOD in any company I ever invest in again. One other will be to take full responsibility for my investment decisions and accept how they turn out. I bugged out right after the ASM ended and didn’t stick around for the tour of Avid. I had a flight to catch. Only one flight I could get to make it home that day. Maybe some of you there could gather more insight in talking with BOD or management during the tour. I went on the Avid tour last year and was impressed with the facilities. FWIW This is what I gathered and is my opinion about the current situation. I saw a group of highly qualified individuals both on the new BOD and new leadership for Avid. These individuals are try to make lemonade out of lemons. Face it folks, after years and years of being told we had a bag of diamonds but we ended up with a bag of lemons! I am not saying that PS/Bavi/IP is worthless. Nobody really knows! Yet! but because the leadership of legacy PPHM did not do the correct things to prove it’s worth, we are left with an IP in shambles. After spending several hundreds of millions they left us with no value for the IP and the only way to prove value of the IP is to spend many more millions. ( A Bag of Lemons) Basically, after Sunrise failure the PPHM leadership decided to spend millions more to search around in the bag of lemons to see if they could just one diamond. We can all speculate on why legacy PPHM leadership continued down their path. Fact to me is last year PPHM had two things. An R&D division with the IP and faced with spending millions more to prove some worth with low chance of success, even lower based on past successes. A CDMO business that with the right leadership and direction could become a nice profitable business in a few years. The chance of success with CDMO is very high IMO and I think valued much higher than R&D portion. I think Ronin saw the CDMO business as a good development opportunity and took it. Real business people made real business decisions with maximum potential and maximum returns in mind. C'est la vie PPHM HELLO CDMO FU#323070: Don't get me wrong. I am not saying IP does not have value! I bought TCLN because I believed it did have value. I could hear the enthusiasm in Dr Thorpe's voice when he presented it. That was powerful! I just think the IP has been squandered all these years and nobody knows how much more money must be spent to realize it's real worth and with failed PIII no one is willing to take a chance on it. Hence, It's not worth much at this point in time. I think best path forward is CDMO to recoup invested money.
FULL HISTORY of PPHM-Ronin PR’s, Letters, 13-D’s, Form4’s, Proxy’s, etc: https://tinyurl.com/ycb3fpfm 12-26-17: Roger Lias replaces Steven King as Pres./CEO; in process of changing name to Avid Bio. and new Nasdaq Ticker ("early 2018") https://tinyurl.com/yb34e2t8
12-11-17: Qtly. Conf. Call (Lias/Lytle) Transcript https://tinyurl.com/ybycb2s6 ...Dr. Lias, "the company is undergoing a broad-scale transformation, the goals of which are to shift complete focus to the Avid Bioservices CDMO business and the complete divestiture of all of Peregrine's legacy R&D assets, which include bavituximab."
1-18-18/2017 ASM: Roger Lias’ Slideshow & Attendee Reports ...Attendee Reports are after the Slides. I will update & re-post as more come in over the next few days. Thanks N40K for your addl. feedback – hopefully more to come.
CEO Roger Lias’ ASM Presentation Slides (1-18-18):
ATTENDEE REPORTS (2017 ASM 1-18-18):
By: Hawkfan1 (Michael) 1-18-18 9:41pmET #322974 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137796412 Here are some of my notes taken at the ASM. They are very brief paraphrases, since I never took shorthand in school. As usual, Brandon Cox was the first to take the microphone with a long list of questions, that at least this shareholder very much appreciated. Q. You are burning $3-4mm/qtr, with no cash and no back log. How do you plan to raise capital? A. Your estimate of our burn rate is in the right ball park. We do have $33mm in backlog, but that is quite conservative. Most companies recognize all of an order when it is placed, but traditionally, PPHM has only recognized backlog as work orders for that order are placed. But clearly, we need more capital. We must eliminate the 'going concern' clause. While it may not be ideal for a small biotech, it is probably something they can live with. But for a manufacturing company, it is a death knell. Customers need to know that you are going to be around for the long term. Q. How dilutive will it be? A. We don't know yet. We don't know how much we will need yet. Q. Is anyone from the old management team working to help sell the R&D technology? A. Yes, Shelly. And others are working as consultants. Q. Most CDMO's are private companies. Are there any plans to take the company private? A. Not currently. (He did mention, kind of jokingly, that it would be nice). Q. Who are the major institutional investors? A. Still Ronan, Tappan, and Eastern Capital. Q. Will they be involved in the capital raise? A. Hopefully. Q. What is the cost of being a public company? A. About $2-3mm/year. Q. As a strictly mfg. company, do we really need 7 board members? A. Right now, the experience that they all bring is extremely helpfull. Down the road, maybe not. Q. How much cash do we currently have? A. $27.7mm. (Not quite sure I got this right, but I think that $10mm was in customer deposits). [NOTE: the $27.7mm is a/o 10-31-17, the last 10-Q (Deposits were $13.1mm): https://tinyurl.com/ybycb2s6 ] Q. Will Avid expand beyond the earthquake prone Tustin area? A. It could be done relatively easily. Down the road, it will be evaluated. Then Brandon relinquished the mike and North40k gave a long and impassioned commentary about various trials and people (such as Dr. Wolchok) that the company should contact about Bavituximab. He mentioned Wolchok's comment that his next trial "depends on the company". Dr. Lias stated that Dr. Wolchok has not contacted the company. He mentioned that an associate of Dr. Wolchok had said that it will be 18 mos. before the next trial proceeds. (This was met with incredulity from several shareholders in attendance). Dr. Lias stated that they have numerous discussions regarding CAR-T, but there was no interest. In some other discussions, they found our technology interesting, but then said "prove it in a trial". N40k then asked if the recent Halozyme trial failure would affect Avid. It will not. Brandon Cox then resumed his questioning. He asked a question regarding the IP patent clock, which I previously reported. For continuity, Dr. Lias's answer was that as patents start to expire, and a BP realizes that it will take about $70mm and 3-4 years to bring a product to market, a 5-year patent life is not that exciting to them. Q. How much Bavi do we have in storage? A. Enough for a couple of small trials, nothing big. Q. Client #1 is Halozyme. We don't know the name of client #2, but are they gone for good? A. No, but I don't expect them to be hugely successful. They will be years down the road. Q. Question regarding the interest in the Exosome test kit. A. Not much commercial interest. Q. Are you trying to sell the IP in bits and pieces or as a package deal? A. While a package deal would be ideal, not gonna happen. Then Greg got up and asked about the process of sell the IP. Dr. Lias commented that there was not much interest. The previous board has talked to everyone - it is not a secret - just not much interest. Then N40k asked the board to contact Precision for Medicine, which concluded the Q&A. Again, this is very roughly paraphrased from my notes. Other members that were in attendance, please correct anything that I may have inadvertently gotten wrong. As I decided to take the tour, I was not able to talk to the board members one on one after the meeting. BY: HAWKFAN1 (MICHAEL) ... 1-18-18 7:54pmET #322954 (INITIAL POST) https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137794640 Dr. Lias comment about the lack of interest in the IP by BP was in response to a question by Brandon Cox about the declining IP clock. His example was that if BP knows that it will take about $70M and 3-4 years of trials to get a drug to market, then a 5-year patent life is just not that exciting to them. This doesn't address the question of getting a patent extension, however. If this is true, then Dr. Lias needs to be made aware of it. FU #323010: Just a few more general impressions from the meeting today. Like the rest of you, I was very disappointed in the approach to marketing the IP. On the one hand, Dr. Lias said that there were on-going discussions that he could not talk about, but he continually down played any expectation that we would receive much value for it. It was almost like they have already given up and have a 'Hey, we tried, but nobody is interested' attitude. They certainly didn't spell out any detailed marketing plan. On the CDMO front, they generally impressed me as qualified, and will probably do a fine job, but I almost choked when Lias said that Tracy Kinjersky "hit the ground running". Hopefully, she will not emulate Mary Boyd. The tour of the Myford facility was as impressive as ever. The 2 new 2000L reactors are installed, tested and ready to go, but have not yet been used in production. Someone asked how many employees we have now and we were told about 200, of which 30 something (I don't remember the exact number) are in production. I asked, if only 30 something are in production, what do the others do? I was told quality control, testing, etc., which I would consider as part of production. This brought the number up to about 75. Unfortunately, we were interrupted, and I wasn't able to pursue this breakdown any further. It seems reasonable to me that we can get to $200mm in sales, but it will be at least 2-3 years down the road. They already have space in the Myford building to build out a duplicate of the existing facility, except that I believe it will use all 2000L reactors. But this space is still raw warehouse space, and will take a minimum of a year to build. And they won't start building it until they have reached significant profits from the exiting facility. So it all hinges on how fast they can attract new clients. FU#323064: re: How many in meeting? I didn't actually count, but I was going to guess that there were probably about 20 shareholders, and we were matched, if not outnumbered, by company employees. My impression was that it was a bit smaller attendance by shareholders than in years past.
By: Holotawoopas 1/18/18 4:49pmET #322902 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137790910 For those who have pinned their hopes on the value of the IP it is time to mourn your loss and move on as there was nothing concrete about any potential monetizing extrapolated at the ASM. N40 gave a valiant effort to plead the case of value of the IP but IMO it fell on deaf ears! The CEO said no BP interest has been received! FU#322909: The CEO stated that the biggest down fall to monetizing the IP has nothing to do with leverage but has everything to do with patent expiration!!!
By: Eb0783 1/18/18 1:45pmET #322864 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137783413 ASM votes: #1 all re-elected, #2 for 36.4mm, #3 for 15.2 v. against 3.6, #4 1 year FU#322879: Per Lias, there is no formal process, group, or investment bank in place to sell the IP. FU#322934: Lias said he wasn't a patent expert when made those comments about short patent life being an issue. It was obvious he wasn't aware that patents could be extended due to years lost in development. Some of us took that short patent life excuse with a grain of salt. FU#323063: re: How many in meeting? I counted about 40 at the start of the meeting. I would guess 50%-60% were shareholders. That is about normal from my experience. I remember counting 40 & 50 in previous ASMs. FU#323066: The thing is, if they are really not having a process, group, or IB in place to evaluate/sell our IP, they don't have to spend anything to do it. At the very least, give the task to some IB or 3rd party expert on contingency: you can keep 50% of whatever you can sell it for. (You lawyers often take cases on the same basis and accept 30, 40, 50% quite often). I said that to Lias after the meeting, with Ziebell & Lytle standing there - no comment from them. I find their stance on this incredulous, if true!
By: Djohn 1-19-18 2:18pmET #323067 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137818937 MY THOUGHTS AFTER THE ASM: I missed the fancy danish, the cream cheese and bagels also missed the fancy hotel backdrop making me think we were on the verge of something astronomical. What did not miss was my thoughts of how many shares had to be sold to pay for me to bite on my bagel, sip on my fine coffee while looking at a beautiful swimming pool at a posh hotel. It’s amazing what can be done with a couple of cases of bottled water, one pot of coffee and a room with chairs. That alone convinced me our new leadership is serious about how they spend the shareholders money! For me the ASM went as I expected. It just confirmed to me that we are no longer chasing a dream. We no longer have a questionable cast of characters spending our money diluting our shares. It’s pretty easy, we are a manufacturing company now with basic straight forward business model. We have people in place who are qualified to grow this business and IMO recoup the total amount I invested in PPHM maybe even more. I have given up the dream! I will awake daily and put on a BaviDermCQ patch. I will develop a 12-step program to wean myself from astronomical thoughts. One of those steps will be to not visit this board as often. Another step will be to fully investigate the members of the BOD in any company I ever invest in again. One other will be to take full responsibility for my investment decisions and accept how they turn out. I bugged out right after the ASM ended and didn’t stick around for the tour of Avid. I had a flight to catch. Only one flight I could get to make it home that day. Maybe some of you there could gather more insight in talking with BOD or management during the tour. I went on the Avid tour last year and was impressed with the facilities. FWIW This is what I gathered and is my opinion about the current situation. I saw a group of highly qualified individuals both on the new BOD and new leadership for Avid. These individuals are try to make lemonade out of lemons. Face it folks, after years and years of being told we had a bag of diamonds but we ended up with a bag of lemons! I am not saying that PS/Bavi/IP is worthless. Nobody really knows! Yet! but because the leadership of legacy PPHM did not do the correct things to prove it’s worth, we are left with an IP in shambles. After spending several hundreds of millions they left us with no value for the IP and the only way to prove value of the IP is to spend many more millions. ( A Bag of Lemons) Basically, after Sunrise failure the PPHM leadership decided to spend millions more to search around in the bag of lemons to see if they could just one diamond. We can all speculate on why legacy PPHM leadership continued down their path. Fact to me is last year PPHM had two things. An R&D division with the IP and faced with spending millions more to prove some worth with low chance of success, even lower based on past successes. A CDMO business that with the right leadership and direction could become a nice profitable business in a few years. The chance of success with CDMO is very high IMO and I think valued much higher than R&D portion. I think Ronin saw the CDMO business as a good development opportunity and took it. Real business people made real business decisions with maximum potential and maximum returns in mind. C'est la vie PPHM HELLO CDMO FU#323070: Don't get me wrong. I am not saying IP does not have value! I bought TCLN because I believed it did have value. I could hear the enthusiasm in Dr Thorpe's voice when he presented it. That was powerful! I just think the IP has been squandered all these years and nobody knows how much more money must be spent to realize it's real worth and with failed PIII no one is willing to take a chance on it. Hence, It's not worth much at this point in time. I think best path forward is CDMO to recoup invested money.
By: North40000 1-22-18 11:33amET #323194 (Initial Main Report) https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137869635 ...Hawkfan posted that my comments to the CDMO BOD at the ASM last Thursday morning seemed to him impassioned. I was not aware of that quality in my remarks. I did try to portray facts, as I knew them, to the BOD, with suggestions as to what that BOD should do to bring increased value to CDMO, PPHM and SH assets/share value or $$$price. Frankly, those facts & remarks seemed to me to fall on deaf ears - the stolid, expressionless faces of BOD members while I spoke made me feel I was talking to an army or array of Chinese stone soldiers. I was pleased to see one BOD member take notes during my presentation (I hope it was not a grocery list for his wife when he returned home). It was like delivering remarks to a judicial bench of judges who were not sufficiently informed of the record [history] before them to know what questions to ask. I began explaining that we had invested in past years some $550k in PPHM therapy technology, and once had ~ 500k shares of PPHM with a break-even point of $1.10/share. Now, with a reverse split behind us together with a change in focus and name of PPHM to CDMO, we hold ~73k shares CDMO with a break-even point of ~ $7.70/share. I expressed my own opinion that the individual new BOD members had the qualifications necessary to bring CDMO share price/value well beyond the above $7.70 eventually. I was a bit dismayed to see from the slides that revenues might increase to $200mm by 2022 from >$100mm in 2018. The identity of further customers signed by Avid/CDMO since Jan.2017 was not further explained. For now, I will not belabor my previous comments as to what Dr. Jedd Wolchok and other MSKCC personnel have told me in face-to-face conversations at SITC 2016, Wistar (Dec. 7, 2016), AACR 2017 or JHU (Johns Hopkins) in Baltimore(Dec. 7, 2017). Nor will I expand my comments re: conversations had with Dr. Nikoletta Kallinteris (PPHM) or Dr. Thomas O’Kleen (Precision for Medicine) at SITC in Nov.2017. My remarks are already recorded here, and my comments last week to the CDMO BOD contain basically the same information, including the fact that Precision for Medicine has acquired $200mm in addl. funds and has >1000 employees world-wide... EARLIER #323153: When I asked PL at ASM what SK is doing these days, PL told me he is occupying his time acting as a kind of entrepreneur… marketing PPHM platform. FU#323169: No mention by any of 6 new BOD members of what you post (Biopharm: GORE Protein Capture Device) at least that I heard. Indeed, but for Dr. Lias, I heard none of the other 5 new BOD members speak at all about anything - all 6 that were there at the front table [one could not attend the ASM at all due to snow in N.Car.] had secreted themselves out of our sight until shortly before 10am, when they all filed in from a heretofore closed door, sat down in chairs with name placards in front of them, were introduced by either the new BOD chairman [who welcomed us and called the meeting to order] or Dr. Lias [I forget which]. The new BOD chair & Dr. Lias had evidently decided who should thereafter speak and run the meeting, and it was all Dr. Lias after that who stepped to the microphone to speak. After the meeting was adjourned post Q&A session, we were in a large group of SHs and employees who lined up in front of that same door mentioned above for an Avid/Myford facility tour. I do not know where the BOD members went, or whether any remaining SHs had an opportunity to speak to them. In a curious way, I personally felt I was back in the courtroom at 717 Madison Place in WashDC, where I had argued many appellate cases before a 5-judge tribunal, sitting at a more elegant bench with placards identifying them by name in front of them. A major difference - at least those judges asked questions.
FULL HISTORY of PPHM-Ronin PR’s, Letters, 13-D’s, Form4’s, Proxy’s, etc: https://tinyurl.com/ycb3fpfm 12-26-17: Roger Lias replaces Steven King as Pres./CEO; in process of changing name to Avid Bio. and new Nasdaq Ticker ("early 2018") https://tinyurl.com/yb34e2t8
12-11-17: Qtly. Conf. Call (Lias/Lytle) Transcript https://tinyurl.com/ybycb2s6 ...Dr. Lias, "the company is undergoing a broad-scale transformation, the goals of which are to shift complete focus to the Avid Bioservices CDMO business and the complete divestiture of all of Peregrine's legacy R&D assets, which include bavituximab."
News 
Market Data 
Discover 
